KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Cash from Financing Activities (2016 - 2025)

West Pharmaceutical Services' Cash from Financing Activities history spans 17 years, with the latest figure at -$11.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 83.02% year-over-year to -$11.7 million; the TTM value through Dec 2025 reached -$185.1 million, up 70.27%, while the annual FY2025 figure was -$185.1 million, 70.27% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$11.7 million at West Pharmaceutical Services, down from -$11.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $300000.0 in Q2 2021 and bottomed at -$271.0 million in Q1 2024.
  • The 5-year median for Cash from Financing Activities is -$66.6 million (2024), against an average of -$86.4 million.
  • The largest annual shift saw Cash from Financing Activities skyrocketed 133.33% in 2021 before it crashed 12166.67% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at -$6.2 million in 2021, then crashed by 53.23% to -$9.5 million in 2022, then plummeted by 1894.74% to -$189.5 million in 2023, then soared by 63.64% to -$68.9 million in 2024, then surged by 83.02% to -$11.7 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Cash from Financing Activities are -$11.7 million (Q4 2025), -$11.5 million (Q3 2025), and -$14.9 million (Q2 2025).